Insurance Challenges with GLP-1 Coverage for Weight Loss
Explore the challenges in insurance coverage for GLP-1 weight-loss medications as demand rises and insurers tighten restrictions.
Novo Nordisk Seeks FDA Approval for Oral Anti-Obesity Drug Amid GLP-1 Market Competition
Novo Nordisk applies for FDA approval of oral anti-obesity drug following Eli Lilly's clinical success, intensifying competition in the GLP-1 diabetes and weight loss market.